Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone that includes a trans-3-hexenoic acid modification to improve stability. It is notable for being an FDA-approved peptide (as Egrifta) for HIV-associated lipodystrophy. Research has focused on its effects on visceral fat reduction, GH stimulation, and metabolic parameters. It represents one of the most clinically validated peptides in the growth hormone category.